Eikon Therapeutics, Inc. (EIKN)

Eikon Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023
Selling, General & Admin	63.29	55.81	58.48
Research & Development	235.95	204.54	207.26
Operating Expenses	299.24	260.34	265.74
Operating Income	-299.24	-260.34	-265.74
Interest Expense	-0.89	-0.03	-0.04
Interest & Investment Income	14.95	16.56	23.74
Other Non Operating Income (Expenses)	-0.02	-0	0.04
Pretax Income	-309.52	-243.81	-242
Net Income	-309.52	-243.81	-242
Net Income to Common	-318.91	-243.81	-242
Shares Outstanding (Basic)	3	3	2
Shares Outstanding (Diluted)	3	3	2
Shares Change (YoY)	-	24.34%	-
EPS (Basic)	-113.67	-96.77	-119.43
EPS (Diluted)	-113.67	-96.77	-119.43
Free Cash Flow	-256.73	-219.6	-219.36
Free Cash Flow Per Share	-91.50	-87.16	-108.26
EBITDA	-281.99	-245.34	-254.31
D&A For EBITDA	17.25	15.01	11.43
EBIT	-299.24	-260.34	-265.74

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q